GlassScriptPhysician profile
Michael Valois
NPI 1679022073
$5,558.05
in general payments reported to CMS, 2019-2025
27 companies · $1,714 in 2025
The $1,714 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $646 · 2022: $801 · 2023: $1,118 · 2024: $1,280 · 2025: $1,714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,111.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,959.18 | 2021-2025 | |
| Janssen Biotech, INC. | $576.87 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $377.96 | 2021-2025 | Entyvio, Gattex, Vpriv |
| Madrigal Pharmaceuticals | $371.68 | 2024-2025 | Rezdiffra, Resmetirom |
| Mallinckrodt Hospital Products INC. | $349.74 | 2022-2025 | Terlivaz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $330.06 | 2021-2025 | Xifaxan |
| Boston Scientific Corporation | $274.51 | 2024-2025 | Overstitch Endoscopic Suturing System, Axios |
| Celgene Corporation | $199.57 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $181.94 | 2024-2025 | Zenpep, Vowst |
| Nestle Healthcare Nutrition INC. | $163.03 | 2021-2023 | |
| Qol Medical, LLC | $126.28 | 2021-2023 | Sucraid |
| Ardelyx, INC. | $120.54 | 2024-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $95.32 | 2022-2024 | Rebyota |
| Merck Sharp & Dohme LLC | $61.70 | 2021-2023 | Dificid |
| Intercept Pharmaceuticals, INC. | $54.69 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $49.60 | 2023-2024 | Hyrimoz |
| Phathom Pharmaceuticals, INC. | $44.90 | 2024-2025 | Voquezna |
| Alnylam Pharmaceuticals INC. | $36.68 | 2022-2023 | Givlaari |
| Ipsen Biopharmaceuticals, INC | $27.10 | 2025 | Iqirvo |
| Novo Nordisk INC | $24.99 | 2025 | Wegovy |
| Gilead Sciences, INC. | $22.72 | 2022 | |
| Digestive Care, INC. | $22.57 | 2025 | Pertzye |
| Organon LLC | $20.07 | 2023 | Renflexis, Hadlima |
| Pfizer INC. | $19.94 | 2023 | |
| Redhill Biopharma INC. | $16.76 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.05 | 2023 | Cyltezo |
| W. L. Gore & Associates, INC. | $14.60 | 2023 | Gore Cardioform Septal Occluder |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Valois listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.